Welcome to our dedicated page for Satellos Bioscience news (Ticker: MSCLF), a resource for investors and traders seeking the latest updates and insights on Satellos Bioscience stock.
Satellos Bioscience Inc. (MSCLF) generates news as a clinical-stage biotechnology company developing SAT-3247, an oral small molecule drug aimed at restoring muscle repair and regeneration in degenerative muscle diseases such as Duchenne muscular dystrophy. Company updates frequently highlight progress in clinical trials, regulatory milestones, and scientific findings related to its AAK1-targeted approach.
News items include announcements on Phase 1a/b results in adults with Duchenne, where Satellos has reported safety, tolerability, and functional measures such as changes in grip strength and respiratory function. Additional releases cover the launch and advancement of LT-001, an open-label, long-term follow-up study in adult males with Duchenne, designed to assess longer-term safety, muscle composition by MRI, functional outcomes, and serum biomarkers.
Satellos also issues news on regulatory interactions and approvals, such as the submission and clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration and authorizations from other global regulators to initiate a randomized, placebo-controlled Phase 2 study of SAT-3247 in ambulatory children with Duchenne. These updates outline study designs, endpoints focused on safety, muscle force, muscle quality, function, and regeneration, and plans for open-label extensions.
Investors and observers can also find coverage of Satellos’ participation in scientific meetings and healthcare investment conferences, where the company presents clinical data and discusses its development plans. This news stream provides context on how Satellos is advancing SAT-3247 and leveraging its MyoReGenX™ discovery platform within the field of degenerative muscle diseases.
Satellos (OTCQB:MSCLF) reported new Phase 1a/b data showing SAT-3247 was safe and well tolerated and produced early functional gains in five adults with Duchenne muscular dystrophy after 28 days.
Key results: maximum grip strength increased mean 118.6% (dominant hand) and 97.9% (non-dominant hand), rising from ~2 kg to ~4 kg; predicted forced vital capacity improved mean 5.8%. No drug-related adverse events of moderate severity or higher and no dose-limiting toxicities were observed. Higher drug concentrations on Day 15 and higher baseline creatinine correlated with greater grip gains.
The five adult participants are invited to an 11-month open-label follow-up, and the company plans a Phase 2 randomized, double-blind, placebo-controlled study in ambulatory children with DMD with regulatory filings submitted.
Satellos Bioscience (OTCQB: MSCLF) announced it will present two scientific posters at the 30th Annual Congress of the World Muscle Society (WMS) in Vienna, Austria, from October 7-11, 2025. The presentations will feature new analyses from the Phase 1b study of SAT-3247, their investigational treatment for Duchenne muscular dystrophy.
The company's Chief Medical Officer, Dr. Wildon Farwell, will present late-breaking data from the Phase 1a/b study in healthy volunteers and adult Duchenne patients. Additionally, Dr. Ryan Mitchell, SVP of Medical & Scientific Affairs, will provide a clinical progress update on SAT-3247, which is designed to address deficits in muscle repair and regeneration.
Satellos Bioscience (OTCQB: MSCLF) has submitted an Investigational New Drug (IND) application to the FDA and parallel regulatory filings globally to initiate a Phase 2 clinical trial of SAT-3247 in children with Duchenne muscular dystrophy (DMD).
The three-month randomized, placebo-controlled study will evaluate safety, pharmacokinetics, and functional measures in ambulatory children, with the first patient enrollment expected by end of 2025. The company's Phase 1b study showed promising results, with patients experiencing doubled grip strength and 5% improvement in lung function.
Additionally, Satellos has initiated an 11-month extension study in Australia and received C$1.04 million through warrant exercises in Q3 2025.
Satellos Bioscience (OTCQB:MSCLF), a clinical-stage biotech company focused on developing treatments for degenerative muscle diseases, has announced its participation in four major healthcare investor conferences this September.
The company will attend the Wells Fargo Healthcare Conference (Sept. 3, Boston), Cantor Fitzgerald Global Healthcare Conference (Sept. 5, New York), H.C. Wainwright Global Investment Conference (Sept. 9, New York), and Morgan Stanley Global Healthcare Conference (Sept. 10, New York). Two of these events will feature fireside chats that will be available via webcast on the company's investor relations website.
Satellos Bioscience (OTCQB: MSCLF) reported positive Phase 1b results for SAT-3247 in treating Duchenne muscular dystrophy (DMD). The trial demonstrated safety and an approximate doubling in grip strength in five adult DMD patients after 28 days of treatment.
The company plans to initiate a follow-up study in Q3 2025, with 3-month interim data expected by year-end. Satellos is also preparing for a global Phase 2 randomized trial in children with DMD, pending regulatory approvals.
Financially, Satellos ended Q2 2025 with $38.2 million in cash, reporting a net loss of $5.6 million ($0.03 per share) compared to $4.4 million ($0.04 per share) in Q2 2024. R&D expenses increased to $4.4 million from $3.6 million year-over-year.
Satellos Bioscience (OTCQB: MSCLF), a clinical-stage biotech company focused on developing treatments for degenerative muscle diseases, has announced its participation in the Canaccord Genuity's 45th Annual Growth Conference. The event will take place on August 13-14, 2025, at the InterContinental Boston.
Management will deliver a presentation on Wednesday, August 13, from 12:30 to 12:55 p.m. ET in Abigail Adams C and will be available for one-on-one meetings. Investors can access the live webcast through the Events and Presentations page in the Investors section of Satellos' website, with a replay available after the event.
Satellos Bioscience (OTCQB: MSCLF) has appointed Dr. Wildon Farwell as Chief Medical Officer to advance their muscle disease therapeutic programs. Dr. Farwell joins from Dyne Therapeutics, where he served as CMO and brings significant expertise in neuromuscular disease drug development.
Dr. Farwell's notable achievements include building Dyne's development organization and leading their DMD and DM1 programs. At Biogen, he led the development of SPINRAZA®, the first approved treatment for spinal muscular atrophy, and initiated late-stage development of QALSODY® for ALS.
In his new role, Dr. Farwell will focus on advancing SAT-3247 into a global Phase 2 clinical trial for children with Duchenne muscular dystrophy (DMD). He succeeds Dr. Jordan Dubow, who will continue as a consultant and Clinical Advisory Board chair.
[ "Appointment of highly experienced CMO with proven track record in neuromuscular disease drug development", "New CMO has successful history of regulatory approvals, including SPINRAZA®", "Progress toward Phase 2 clinical trial for SAT-3247 in DMD treatment" ]